| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cimicoxib targets COX-2, acting as a selective inhibitor. It has an IC50 of 66 nM against human COX-2. It shows selectivity for COX-2 over COX-1 (IC50 = 1900 nM). By inhibiting COX-2, it reduces the production of prostaglandins that cause inflammation and pain. It also exerts targeted inhibition on CYP2D15.
|
|---|---|
| ln Vitro |
In vitro, Cimicoxib inhibits COX-2 with an IC50 of 66 nM. It shows selectivity for COX-2 over COX-1 (IC50 = 1900 nM). It inhibits the production of thromboxane B2 and prostaglandin E2. It displays significant anti-inflammatory activity.
|
| ln Vivo |
In vivo, Cimicoxib is used in veterinary medicine to control pain and inflammation associated with osteoarthritis and perioperative pain. It is orally active and blood-brain barrier-permeable. It is being investigated for the treatment of major depression and schizophrenia.
|
| Enzyme Assay |
In vitro enzyme assays for Cimicoxib typically measure its inhibition of COX-1 and COX-2 activity. The enzymes are incubated with arachidonic acid in the presence of varying concentrations of the compound. Prostaglandin production is measured by ELISA or by using a chromogenic substrate. IC50 values are calculated from inhibition curves.
|
| Cell Assay |
Cellular assays for Cimicoxib are performed using cells that express COX-2, such as macrophages or cancer cells. Cells are stimulated with LPS to induce COX-2 expression, and then treated with the compound. Prostaglandin E2 production is measured by ELISA. Cell viability is assessed to rule out cytotoxicity.
|
| Animal Protocol |
In vivo animal studies with Cimicoxib are conducted in models of inflammation and pain, such as the carrageenan-induced paw edema model. The compound is administered orally. Paw swelling and pain threshold are measured. Its efficacy in reducing inflammation and pain is assessed. Its effects in models of depression and schizophrenia are also being investigated.
|
| ADME/Pharmacokinetics |
Cimicoxib is orally active. It is blood-brain barrier-permeable. Its molecular weight is 381.81 g/mol. The compound has a molecular formula of C20H19ClFN3O2. For research use, it is typically dissolved in DMSO for in vitro studies. Its half-life and metabolic profile have been characterized in veterinary studies.
|
| Toxicity/Toxicokinetics |
Cimicoxib is generally well tolerated. Side effects may include gastrointestinal disturbances, similar to other COX-2 inhibitors. Its safety profile has been evaluated in veterinary studies. It is being investigated for its potential in treating depression and schizophrenia.
|
| Additional Infomation |
Cimecoxib is an imidazole compound with its 1, 4, and 5 positions substituted with 4-aminosulfonylphenyl, chlorine, and 3-fluoro-4-methoxyphenyl, respectively. It is a selective cyclooxygenase-2 inhibitor used in veterinary medicine to control pain and inflammation associated with osteoarthritis in dogs. It is both a cyclooxygenase-2 inhibitor and a nonsteroidal anti-inflammatory drug (NSAID). It belongs to the sulfonamide, imidazole, organochlorine, organofluorine, and aromatic ether classes. Cimecoxib is a selective COX-2 inhibitor developed by Affectis for the treatment of depression and schizophrenia. If approved, cimecoxib will be the first drug in decades to treat depression through a novel mechanism of action. Drug Indications Studied for the treatment of depression. Relieving pain and inflammation associated with osteoarthritis. Treatment of perioperative pain following orthopedic or soft tissue surgery. Mechanism of Action Both depression and schizophrenia are inflammatory diseases. Elevated levels of pro-inflammatory cytokines and prostaglandin E (PGE) in patients with major depressive disorder have been repeatedly confirmed. COX-2 inhibitors can inhibit the production of both. Cimecoxib is a selective COX-2 inhibitor. The mechanism by which some COX-2 inhibitors treat depression may be related to their anti-inflammatory mechanisms.
Cimicoxib is a selective COX-2 inhibitor used in veterinary medicine for the treatment of pain and inflammation in dogs. It is orally active and blood-brain barrier-permeable. The compound is also being investigated for the treatment of major depression and schizophrenia. Cimicoxib is not approved for human use but has shown promise in clinical trials for psychiatric indications. |
| Molecular Formula |
C16H13CLFN3O3S
|
|---|---|
| Molecular Weight |
381.8064
|
| Exact Mass |
381.035
|
| CAS # |
265114-23-6
|
| PubChem CID |
213053
|
| Appearance |
White to off-white solid powder
|
| Density |
1.49g/cm3
|
| Boiling Point |
593.1ºC at 760 mmHg
|
| Flash Point |
312.5ºC
|
| Vapour Pressure |
4.91E-14mmHg at 25°C
|
| Index of Refraction |
1.649
|
| LogP |
4.768
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
553
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=C(C2C=CC(OC)=C(F)C=2)N(C2C=CC(S(N)(=O)=O)=CC=2)C=N1
|
| InChi Key |
KYXDNECMRLFQMZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23)
|
| Chemical Name |
4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide
|
| Synonyms |
UR8880; UR8880; UR-8880
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~327.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6191 mL | 13.0955 mL | 26.1910 mL | |
| 5 mM | 0.5238 mL | 2.6191 mL | 5.2382 mL | |
| 10 mM | 0.2619 mL | 1.3096 mL | 2.6191 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
